Anemia In Chronic Kidney Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for anemia in chronic kidney disease. 30 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
30
Active US patents
69/100
Avg vulnerability
—
Annual revenue covered

Originators in Anemia In Chronic Kidney Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

GSK 30 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating anemia in chronic kidney disease. Each bar = one year. Y-axis scaled to peak year (15 patents).

15
27
5
28
10
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Jesduvroq
DAPRODUSTAT
 GSK 30 69 — 2027-06-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8815884 Jesduvroq method of use 83 2027-06-22
8815884 Jesduvroq method of use 83 2027-06-22
8815884 Jesduvroq method of use 83 2027-06-22
11643397 Jesduvroq method of use 83 2027-06-22
8557834 Jesduvroq method of use 83 2027-06-22
11643397 Jesduvroq method of use 83 2027-06-22
8815884 Jesduvroq method of use 83 2027-06-22
11643397 Jesduvroq method of use 83 2027-06-22
8557834 Jesduvroq method of use 83 2027-06-22
11643397 Jesduvroq method of use 83 2027-06-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8324208 Jesduvroq composition of matter 25 2028-12-11
8324208 Jesduvroq composition of matter 25 2028-12-11
8324208 Jesduvroq composition of matter 25 2028-12-11
8324208 Jesduvroq composition of matter 25 2028-12-11
8324208 Jesduvroq composition of matter 25 2028-12-11
11117871 Jesduvroq method of use 70 2038-03-13
11117871 Jesduvroq method of use 70 2038-03-13
11649217 Jesduvroq method of use 70 2038-03-13
11117871 Jesduvroq method of use 70 2038-03-13
11117871 Jesduvroq method of use 70 2038-03-13

Related